新型冠状病毒肺炎与肾素-血管紧张素系统相关研究进展  

Novel coronavirus disease-2019 and renin-angiotensin system

作　　者：卢虎 郑义山 LU Hu;ZHENG Yi-shan(Department of Critical Medicine,Nanjing Second Hospital,Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine,Nanjing,Jiangsu 210003,China)

机构地区：[1]南京中医药大学附属南京医院南京市第二医院重症医学科,江苏南京210003

出　　处：《中国临床研究》2022年第6期840-843,共4页Chinese Journal of Clinical Research

摘　　要：目前,世界爆发的新型冠状病毒肺炎(COVID-19)受到国内外的广泛关注。有研究显示,介导新型冠状病毒(2019-nCoV)跨物种传播受体与SARS冠状病毒(SARS-CoV)一致,均为血管紧张素转化酶-2(ACE2)。肾素-血管紧张素(RAS)系统是机体内关键的体液调节系统,在心血管功能稳态及电解质体液平衡调节中发挥着重要作用。在全国抗“疫”的形势下,2019-nCoV与RAS系统的相关研究受到临床医生的关注和重视。本文就当前关注的热点,包括COVID-19、ACE2、ACE抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)类药物及其相关性的研究进展作一综述。Nowadays, the outbreak of the novel coronavirus disease-2019(COVID-19) in the world has attracted widespread attention at home and abroad. Studies have shown that the receptor that mediates cross-species transmission of 2019-new coronavirus(2019-nCoV) is consistent with SARS-CoV, both of which are angiotensin converting enzyme-2(ACE2). The renin-angiotensin system(RAS) is a key humoral regulation system in the body and plays an important role in the regulation of cardiovascular function homeostasis and water-electrolyte balance. Under the situation of national anti-epidemic, the research on 2019-nCoV and RAS system has attracted attention from clinicians. This article will review the current hot topics, including COVID-19, ACE2, ACE inhibitor(ACEI)/angiotensin receptor blocker(ARB) drugs and their related research progress.

关 键 词：新型冠状病毒肺炎 血管紧张素转化酶-2 血管紧张素转化酶抑制剂 血管紧张素受体阻滞剂 

分 类 号：R511[医药卫生—内科学]